DMTK vs Diagnostics & Research Stocks
| Ticker | Price | Price Target | Up/downside | Consensus |
| DMTK | $6.37 | $26.75 | +319.94% | Strong Buy |
| PSNL | $4.03 | $23.00 | +470.72% | Buy |
| CODX | $5.98 | $12.00 | +100.67% | Buy |
| DRIO | $6.75 | $19.00 | +181.48% | Strong Buy |
| High | $48.00 |
|---|---|
| Median | $27.00 |
| Low | $19.00 |
| Average | $29.67 |
| Current Price | $7.24 |
What are analysts'price targets for dermtech's stock?
7 equities research analysts have issued 12-month price targets for DermTech's stock. Their forecasts range from $20.00 to $79.00. On average, they anticipate DermTech's stock price to reach $56.00 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price.
Is dermtech (dmtk) a buy or sell?
According to the issued ratings of 4 analysts in the last year, the consensus rating for DermTech stock is Buy based on the current 1 hold rating and 3 buy ratings for DMTK. The average twelve-month price target for DermTech is $58.75 with a high price target of $79.00 and a low price target of $48.00.
Does dermtech's stock have an upside of 62%?
Does DermTech's stock price have much upside? According to analysts, DermTech's stock has a predicted upside of 62.52% based on their 12-month price targets. What analysts cover DermTech?
How much is a share of dermtech worth?
One share of DMTK stock can currently be purchased for approximately $11.85. How much money does DermTech make? DermTech has a market capitalization of $352.15 million and generates $5.89 million in revenue each year. The company earns $-35.25 million in net income (profit) each year or ($2.30) on an earnings per share basis.
Is DermTech stock a good buy?
DermTech has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Will DermTech stock go up?
Stock Price Forecast The 6 analysts offering 12-month price forecasts for DermTech Inc have a median target of 27.00, with a high estimate of 48.00 and a low estimate of 19.00. The median estimate represents a +273.19% increase from the last price of 7.24.
Is DermTech publicly traded?
Common Stock (DMTK)
Is DermTech a good company?
DermTech is a small molecular diagnostic company with lots of potential. They offer flexible work schedules and free snacks in the break room. The work culture is relaxed and since it is a small company there is potential to learn lot of new techniques.
Is DermTech profitable?
Earnings and Revenue History Quality Earnings: DMTK is currently unprofitable. Growing Profit Margin: DMTK is currently unprofitable.
Is DermTech FDA approved?
This test was developed and its performance characteristics determined by DermTech. It has not been cleared or approved by the US Food and Drug Administration; FDA does not require this test to go through premarket FDA review. This test is used for clinical purposes.
When did DermTech go public?
September 17, 2020333-248642) that was filed with the Securities and Exchange Commission (the “SEC”) on September 8, 2020 and declared effective by the SEC on September 17, 2020 .
What is DermTech's consensus rating and price target?
According to the issued ratings of 3 analysts in the last year, the consensus rating for DermTech stock is Buy based on the current 1 hold rating a...
Do Wall Street analysts like DermTech more than its competitors?
Analysts like DermTech stock less than the stock of other Medical companies. The consensus rating score for DermTech is 2.67 while the average cons...
Do MarketBeat users like DermTech more than its competitors?
MarketBeat users like DermTech stock less than the stock of other Medical companies. 66.13% of MarketBeat users gave DermTech an outperform vote wh...
Does DermTech's stock price have much upside?
According to analysts, DermTech's stock has a predicted upside of 116.33% based on their 12-month price targets.
What analysts cover DermTech?
DermTech has been rated by BTIG Research , and Cowen in the past 90 days.
Should I buy or sell DermTech stock right now?
3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last twelve months. There are currently 1 hold ra...
What is DermTech's stock price forecast for 2022?
3 Wall Street research analysts have issued 12 month price objectives for DermTech's stock. Their forecasts range from $20.00 to $38.00. On average...
How has DermTech's stock performed in 2022?
DermTech's stock was trading at $15.80 on January 1st, 2022. Since then, DMTK stock has decreased by 67.3% and is now trading at $5.17. View the b...
When is DermTech's next earnings date?
DermTech is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for DermTech .
How were DermTech's earnings last quarter?
DermTech, Inc. (NASDAQ:DMTK) released its quarterly earnings data on Tuesday, May, 3rd. The company reported ($1.01) earnings per share (EPS) for t...
Who are DermTech's key executives?
DermTech's management team includes the following people: Dr. John D. Dobak M.D. , Pres, CEO & Director (Age 56, Pay $783.41k) Mr. Kevin Sun M.B...
Who are some of DermTech's key competitors?
Some companies that are related to DermTech include Invitae (NVTA) , Castle Biosciences (CSTL) , Viridian Therapeutics (VRDN) , Burning Rock Bi...
What other stocks do shareholders of DermTech own?
Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE) , CrowdStrike...
What is DermTech's stock symbol?
DermTech trades on the NASDAQ under the ticker symbol "DMTK."
DermTech to Announce Fourth Quarter and Full-Year Financial Results
LA JOLLA, Calif., February 15, 2022--DermTech, Inc. (NASDAQ: DMTK) ("DermTech"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it plans to release its fourth quarter and full-year 2021 financial results after the market closes on Tuesday, March 1, 2022.
Is DermTech, Inc.'s (NASDAQ:DMTK) Shareholder Ownership Skewed Towards Insiders?
If you want to know who really controls DermTech, Inc. ( NASDAQ:DMTK ), then you'll have to look at the makeup of its...
Ausdal Financial Partners, Inc. Buys Ford Motor Co, Uber Technologies Inc, SPDR Portfolio ..
Investment company Ausdal Financial Partners, Inc.
Stock Price Forecast
The 6 analysts offering 12-month price forecasts for DermTech Inc have a median target of 49.00, with a high estimate of 79.00 and a low estimate of 26.00. The median estimate represents a +299.67% increase from the last price of 12.26.
Analyst Recommendations
The current consensus among 7 polled investment analysts is to Buy stock in DermTech Inc. This rating has held steady since January, when it was unchanged from a Buy rating. Move your mouse over past months for detail
What is Dermtech stock price prediction?
Dermtech stock price prediction is an act of determining the future value of Dermtech shares using few different conventional methods such as EPS estimation, analyst consensus, or fundamental intrinsic valuation . The successful prediction of Dermtech stock future price could yield a significant profit.
Does Dermtech have a cover story?
The number of cover stories for Dermtech depends on current market conditions and Dermtech's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Dermtech is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Dermtech's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
DMTK earnings per share forecast
What is DMTK 's earnings per share in the next 3 years based on estimates from 3 analyst s?
DMTK revenue forecast
What is DMTK 's revenue in the next 3 years based on estimates from 3 analyst s?
DMTK revenue growth forecast
How is DMTK forecast to perform vs Diagnostics & Research companies and vs the US market?
